Welcome to our dedicated page for Innoviva news (Ticker: INVA), a resource for investors and traders seeking the latest updates and insights on Innoviva stock.
Innoviva, Inc. Common Stock (INVA) is an innovative biopharmaceutical company focused on bringing compelling new medicines to patients in areas of unmet need. Leveraging its significant expertise in development, commercialization, and financial management, Innoviva has established a diverse portfolio that includes royalty assets and strategic healthcare investments.
Innoviva's primary assets are anchored in respiratory therapies, specifically those partnered with Glaxo Group Limited (GSK). The company is entitled to receive royalty revenues from key products such as Relvar®/Breo® Ellipta®, Anoro® Ellipta®, and potentially VI monotherapy if approved and commercialized. These products were jointly developed with GSK, showcasing a strong collaboration that significantly contributes to Innoviva's revenue stream.
In addition to its respiratory portfolio, Innoviva holds a 15% economic interest in future payments made by GSK for early-stage programs partnered with Theravance Biopharma, Inc. This strategic investment underlines Innoviva's commitment to fostering innovation in the biopharmaceutical industry.
More recently, Innoviva has expanded its footprint in critical care and infectious diseases through strategic acquisitions and partnerships. Notably, the company, via its subsidiary Innoviva Strategic Opportunities LLC, has entered into a secured credit agreement with Armata Pharmaceuticals, Inc., providing $35 million to advance Armata's lead therapeutic phage candidates. This financing underscores Innoviva's dedication to supporting groundbreaking therapies for antibiotic-resistant infections.
Furthermore, Innoviva’s product offerings extend beyond respiratory treatments to include other critical healthcare assets, such as Trelegy Ellipta®. The company's well-rounded portfolio ensures a balanced approach to addressing various healthcare challenges.
Innoviva continually strives to maximize shareholder value through strategic investments and partnerships, robust financial performance, and a commitment to advancing innovative medical solutions. For more detailed information about Innoviva, please visit their official website at www.inva.com.
Innoviva (Nasdaq: INVA), a diversified holding company with a core royalties portfolio and a strong presence in critical care and infectious disease through Innoviva Specialty Therapeutics (IST), announced that its CEO, Pavel Raifeld, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference. The event will take place in Miami, FL on June 10, 2024, at 1:20 p.m. Eastern Time. The session will be available via live webcast on the company's Investor Relations webpage and can be replayed for 90 days.
Innoviva, Inc. (NASDAQ: INVA) reported strong first quarter financial results with $61.9 million in GSK royalties, $19.1 million in net product revenues, and a successful pipeline. The company highlighted positive Phase 3 zoliflodacin clinical trial results and key appointments.
Innoviva, Inc. (NASDAQ: INVA) will participate in the BofA Securities Health Care Conference. The company, a holding firm with a core royalties portfolio and a strong presence in critical care and infectious disease treatment, will have its CEO, Pavel Raifeld, present at the conference on May 15, 2024. Interested parties can access a live webcast of the event on the company's Investor Relations website.
FAQ
What does Innoviva, Inc. specialize in?
What are Innoviva's primary products?
Who are Innoviva's main partners?
What recent financial agreements has Innoviva entered into?
How does Innoviva generate revenue?
What is Innoviva's role in the development of respiratory therapies?
What strategic areas is Innoviva investing in?
What is Innoviva’s relationship with Theravance Biopharma?
Where can I find more information about Innoviva?
What are Innoviva's latest projects?
